The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for durvalumab (AstraZeneca Pty Ltd)
Active ingredients
durvalumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platin-based chemoradiation therapy
Therapeutic area
Oncology